SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
Montreal, July 5, 2024 – Canada’s two health technology assessment (HTA) agencies have made conflicting recommendations on two gene therapies for hemophilia B. Earlier in...
It is safe to say that research provides better quality of life and will lead, one day, inevitably to cures. This is why the Canadian...
Montreal, March 26, 2024 – Developments in gene therapy for hemophilia B have come fast and furious over the last several months. In October 2023,...
